Atyr Pharma (ATYR) | Stock Overview & Key Data
Atyr Pharma Performance Comparison
Stock Range
Today's Range
Low: $4.47
High: $4.76
on August 1, 2025
52 Week Range
Low: $1.67
High: $7.29
on October 1, 2024
on July 28, 2025
All-Time High: $7.29 on July 28, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$418.3M
EPS
-0.80
P/E Ratio (TTM)
-5.47
Forward P/E
-5.95
P/B Ratio
5.58
PEG Ratio
-5.95
Div. Yield
N/A
ROE
-79.70%
Beta
0.898
Debt to Equity
17.35
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-28,899.57%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-39.82%
Return on Equity (TTM)
-79.70%
EBITDA
$-66.4M
Net Income (TTM)
$-63.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.00
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
-100.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Atyr Pharma ATYR | 418.32M Small-cap | -19.38% | -8.38% | 40.72% | 31.65% | 20.20% | 156.83% | 171.68% | 171.68% |
| Vertex VRTX | 118.67B Large-cap | -1.60% | 2.20% | -7.36% | -1.75% | 13.89% | -6.54% | 60.45% | 69.28% |
| Regeneron REGN | 58.89B Large-cap | -0.75% | 4.48% | -5.28% | -16.19% | -21.86% | -48.36% | -8.92% | -9.89% |
| Harmony Biosciences HRMY | 1.98B Small-cap | -8.32% | 7.40% | 15.20% | -11.75% | -1.23% | 6.17% | -34.48% | -4.44% |
| Denali Therapeutics DNLI | 1.95B Small-cap | -1.68% | -3.66% | -16.31% | -38.46% | -35.51% | -38.55% | -62.41% | -57.48% |
| Amicus Therapeutics FOLD | 1.95B Small-cap | 4.29% | 8.22% | -5.39% | -34.44% | -32.12% | -37.30% | -48.11% | -58.99% |
Ownership & Short Interest
Insider Ownership
2.23%
Institutional Ownership
70.54%
Shares Short
20M
Short Ratio
5.25
Short % of Shares Outstanding
27.94%
Average 10-Day Volume
8M
Average 90-Day Volume
6M
Atyr Pharma Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Atyr Pharma would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ATYR's 52-week high and low?
- In the last 52 weeks, Atyr Pharma reached a high of $7.29 (on July 28, 2025) and a low of $1.67 (on October 1, 2024).
- What is the market cap and P/E ratio for ATYR?
- Curious about Atyr Pharma's size and valuation? Its market capitalization stands at 418.32M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.47, and the forward P/E (looking ahead) is -5.95.
- Does ATYR pay dividends? If so, what's the yield?
- As for dividends, Atyr Pharma isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Atyr Pharma's main competitors or similar companies to consider before investing?
When looking at Atyr Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX118.67B Healthcare Biotechnology -6.54% 60.45% Regeneron
REGN58.89B Healthcare Biotechnology -48.36% -8.92% Harmony Biosciences
HRMY1.98B Healthcare Biotechnology 6.17% -34.48% Denali Therapeutics
DNLI1.95B Healthcare Biotechnology -38.55% -62.41% Amicus Therapeutics
FOLD1.95B Healthcare Biotechnology -37.30% -48.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Atyr Pharma Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Atyr Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -79.70%, the Debt to Equity ratio from the most recent quarter is 17.35, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ATYR?
- Looking at Atyr Pharma's growth, its revenue over the trailing twelve months (TTM) was $235K. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of -100.00%.
- How much of ATYR stock is held by insiders and institutions?
- Wondering who owns Atyr Pharma stock? Company insiders (like executives and directors) hold about 2.23% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 70.54%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.